An interventional study of Eskimo-3 Pure Fish Oil and Rapeseed Oil in Leukemia, Acute Lymphoblastic, sponsored by Rigshospitalet, Denmark. Recruiting at 4 sites in Denmark. Open to participants aged 1 Year to 45 Years. Per ClinicalTrials.gov, last updated 2019-12-26.
Sponsored by Rigshospitalet, Denmark · Not applicable, Interventional, and Prevention
Acute lymphoblastic leukemia (ALL) is the most common malignant disease among children. Treatment results have improved over time due to intensive risk-adapted therapy and the 5-year survival rate is now above 90%. However, the burden of therapy has increased proportionally. Many children develop serious acute and chronic side effects, which impact on the patients expected lifespan and impair their quality of life as a result of therapy. Treatment with PEG-asparaginase and dexamethasone increases the levels of triglycerides and total cholesterol. Consequently, the incidence of hyperlipidemia is high during initial ALL therapy. Studies have suggested that hyperlipidemia is a risk factor for development of osteonecrosis, thrombosis and possibly acute pancreatitis.
Long-chained marine omega-3 fatty acids, found in fish oil, decrease levels of triglycerides and total cholesterol in hyperlipidemic patients. Due to the high survival rate, it is of great interest to develop methods to reduce treatment related toxicities.
The investigators hypothesise that daily intake of fish oil will prevent development of hyperlipidemia during ALL treatment phases with dexamethasone and PEG-asparaginase compared to placebo and that fish oil intake may reduce the incidence of severe adverse events related to ALL treatment.
5,441 studies on the registry are indexed under Leukemia; 636 are open to participants now.
This study's planned enrollment of 100 is above the median of 38 across 4,247 interventional studies indexed under Leukemia.
Browse Leukemia studies →Rigshospitalet, Denmark is the lead sponsor of 1,017 studies on the registry; 183 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Eskimo-3 Pure Fish Oil, 10 ml per day (2.6 g EPA+DHA)
Dietary Supplement: Eskimo-3 Pure Fish Oil
Rapeseed Oil, 10 ml per day
Dietary Supplement: Rapeseed Oil
Dosage: 10 ml/day (2.6 g EPA+DHA)
Also known as: Fish Oil
Dosage: 10 ml/day (0 g EPA+DHA)
Also known as: Placebo
Hyperlipidemia
Triglycerides and/or total cholesterol levels five times or more than the age-dependent upper normal limit.
Time frame: From treatment day 4 until treatment day 169 or 204
Lipid metabolism
Triglycerides, total cholesterol, VLDL-cholesterol, LDL-cholesterol and HDL-cholesterol.
Time frame: VLR and IR-low: 4, 11, 18, 25, 32, 39, 46, 53, 60, 67, 81, 95, 109, 123, 137, 151 and 169. IR-high: treatment day 4, 11, 18, 25, 32, 39, 46, 53, 60, 67, 74, 81, 88, 95, 102, 109, 123, 137, 151, 165, 179, 193 and 204.
Compliance
Assessed by self-registration forms, return of bottles and levels of EPA+DHA in whole blood
Time frame: From treatment day 4 until end of intervention (treatment day 169 or 204)
Bone density
Assessed by DEXA-scan and bone biomarkers (iCa, PTH, vit D, phosphate, magnesium, creatinine, alkaline phosphatase, CTX, P1NP.
Time frame: DEXA-scan at start and end of intervention. Bone biomarkers at treatment day 4, 81 and 169 for VLR and treatment day 4, 102 and 204 for IR-low and IR-high.
Hemostatic status
Thromboelastography (TEG), multiplate and thrombocytes.
Time frame: At treatment day 4, 81 and 169 for VLR and at treatment day 4, 102 and 204 for IR-low and IR-high
Endothelial function
sTM, syndecan-1, PECAM, VEGFR1
Time frame: At treatment day 4, 81 and 169 for VLR and at treatment day 4, 102 and 204 for IR-low and IR-high
Incidence of severe adverse events
Cumulative incidence of osteonecrosis, asparaginase associated pancreatitis and thrombosis.
Time frame: From treatment day 4 until end of intervention (treatment day 169 or 204)
Milder side effects
Assessed by questionnaire.
Time frame: At end of intervention (day 169 or 204)
Dietary intake
Assessed by 3-day food records
Time frame: At treatment day 4, 81 and 169 for VLR and at treatment day 4, 102 and 204 for IR-low and IR-high
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Rigshospitalet, Denmark